Fundz

Tempest Therapeutics

Brisbane, California, United States · Biopharma, Biotechnology, Healthcare

Tempest Therapeutics is a development-stage biotechnology company.

Key facts

Headquarters
Brisbane, California, United States
Employees
24
Industries
Biopharma, Biotechnology, Healthcare
Status
Public (TPST)
Website
tempesttx.com
LinkedIn
Company page

Recent activity at Tempest Therapeutics

  • : Tempest Therapeutics names Stephanie Horn-Warnock CFO, Treasurer, & Corp Sec.
  • : Tempest Therapeutics Appoints John Frederick as Class III Director
  • : Tempest Therapeutics Signs Master Services Agreement with Factor Bioscience (date Fundz recorded it)
  • : Tempest Therapeutics
  • : SEC 8-K (8.01): On November 11, 2026, the Company, Tempest Therapeutics, Inc., exercised its option to obtain an exclusive license under its collaboration agreement with Hebei Senlang Biotechnology Co., Ltd. This action allows Tempest to develop and commercialize Senlang's CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates globally, excluding China. This strategic move may enhance Tempest's position in the CAR-T therapy space, potentially leading to new treatment options for patients. The collaboration agreement was originally dated September 14, 2026, and this licensing decision signifies a critical step in their partnership.
  • : SEC 8-K (5.02):
  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On September 22, 2026, Tempest Therapeutics, Inc. entered into a Master Services Agreement (MSA) with Factor Bioscience Inc. The MSA outlines the terms under which Factor will provide research and development services to Tempest, aimed at supporting Tempest’s ongoing development activities. This agreement is crucial as it relates to Tempest's obligations under a prior License and Collaboration Agreement with Factor Bioscience Limited, effective since August 6, 2025. The strategic partnership enhances Tempest's capabilities in developing its biopharmaceutical products and establishes a framework for future collaborative projects.
  • : SEC 8-K (1.01): On September 11, 2026, Tempest Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor to issue pre-funded warrants for the purchase of 3,105,591 shares of common stock, alongside Series C and D warrants. The total gross proceeds from the private placement amount to approximately $2.5 million, facilitating working capital and general corporate purposes. The closing of this private placement occurred on September 15, 2026. Notably, the company will seek stockholder approval for warrant issuance within 90 days and has agreed to various conditional restrictions concerning stock and registration statements for a defined period following the agreement.
  • : SEC 8-K (8.01): On September 15, 2026, Tempest Therapeutics, Inc. reconvened its Special Meeting of stockholders, which had been previously adjourned twice since July 27, 2026. The primary purpose of this meeting was to obtain approval for a Certificate of Amendment to the company's Restated Certificate of Incorporation. This amendment seeks to modify specified supermajority voting requirements and allow stockholder action by written consent, potentially simplifying governance and decision-making processes. The details of the amendment are outlined in the proxy statement attached as Exhibit A.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Tempest Therapeutics funding history

DateRoundAmount
Sep 2026Venture$7.5M
May 2026Venture$4.1M
Mar 2026Venture$2.0M
May 2022Venture$15.0M
Mar 2018Venture$25.2M

Leadership

  • Matt Angel, President and CEO
  • Stephen Brady, Director
  • Michael Raab, Director
  • Robert Weisskoff, Director
  • Stella Xu, Director
  • Thomas Woiwode, Director
  • Petpiboon Prasit, Director
  • Bradley Bolzon, Director
  • Thomas Jr., Executive Officer, Director

Verified email and direct lines for Tempest Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Tempest Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Tempest Therapeutics in the news

Companies similar to Tempest Therapeutics

About Tempest Therapeutics: questions and answers

What does Tempest Therapeutics do?

Tempest Therapeutics is a development-stage biotechnology company.

Where is Tempest Therapeutics headquartered?

Tempest Therapeutics is headquartered in Brisbane, California, United States.

How many employees does Tempest Therapeutics have?

Tempest Therapeutics has about 24 employees.

Has Tempest Therapeutics raised funding?

Yes. Fundz has recorded 5 funding events for Tempest Therapeutics. The most recent, $7.5M, was in Sep 2026.

Who leads Tempest Therapeutics?

Matt Angel is a President and CEO at Tempest Therapeutics.

What is the latest news on Tempest Therapeutics?

On Nov 4, 2026, Tempest Therapeutics names Stephanie Horn-Warnock CFO, Treasurer, & Corp Sec.

Is Tempest Therapeutics a public company?

Yes. Tempest Therapeutics is publicly traded under the ticker TPST.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Tempest Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.